BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for metabolic diseases by targeting the biology of human aging. The company is advancing its lead product candidate, BGE-102, an oral NLRP3 inhibitor, for obesity and cardiovascular risk factors, along with other programs targeting metabolic aging.
In the third quarter of 2025, BioAge Labs achieved significant milestones, including dosing the first participant in a Phase 1 trial of BGE-102 and progressing its APJ agonist programs. The company also reported collaboration revenue of $2.1 million, attributed to its partnership with Novartis, and a net loss of $20.2 million, showing improvement from the previous year.
Key highlights include the advancement of BGE-102 into clinical development, with initial data expected by year-end, and the continuation of APJ agonist programs targeting 2026 IND submissions. Strategic partnerships with Novartis and Lilly are progressing, focusing on novel therapeutic targets for metabolic aging.
Financially, BioAge reported a decrease in research and development expenses due to the termination of azelaprag development, offset by increased costs in other programs. General and administrative expenses rose due to higher legal fees and personnel costs. The company holds approximately $295.9 million in cash and securities, sufficient to fund operations through 2029.
Looking forward, BioAge Labs remains committed to executing its strategic initiatives to develop transformative therapies targeting metabolic aging, with a focus on advancing its clinical trials and partnerships.